Next Article in Journal
In Vitro Study on Antihypertensive and Antihypercholesterolemic Effects of a Curcumin Nanoemulsion
Previous Article in Journal
Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2016, 84(1), 113-130; doi:10.3797/scipharm.ISP.2015.04

Removing a Cystein Group On Interferon Alpha 2b at Position 2 and 99 does Not Diminish Antitumor Activity of the Protein, Even Better

1
School of Pharmacy, Bandung Institute of Technology, Ganesha 10, 40132, Bandung, Indonesia.
2
Department of Pharmacokinetics and Drug Delivery, University of Groningen, Antonius Deusinglaan I, Groningen, Netherlands.
3
Research Center for Biotechnology, Indonesian Institute of Sciences, Jalan Raya Bogor KM 46, 16911, Cibinong, Indonesia.
*
Author to whom correspondence should be addressed.
Received: 5 September 2015 / Accepted: 15 December 2015 / Published: 14 February 2016
Download PDF [398 KB, uploaded 7 September 2016]

Abstract

Interferon alpha 2b is the only standard therapeutic protein for hepatitis virus infections. Further study demonstrated that this protein also posseses antitumor activity in several cancerous organs. One main pathway of this antitumor activity is mediated through antiproliferation as well as proapoptotic effects. Previously, we have successfully developed recombinant human interferon alpha 2b (rhIFNα2b) by using a synthetic gene. In addition, two mutein forms of rhIFNα2b were generated to improve the characteristics of this protein. Two point mutations showed better pharmacokinetic profiles than one point mutation as well as the native form. In the present study, this mutein form was studied for ist antitumor effect in vitro using HepG2 cells. As a comparison, the native form as well as a commercial rIFNα2b were used. Several parameters were investigated including the MTT assay, cell viability test, cell cycle using flow cytometric analysis, and the genes and protein expressions involved in cell growth. The latest was observed to study the mechanism of rhIFNα2b. There was no significant difference in the MTT assay and cell viability after cells were treated with both forms of rhIFNα2b. However, the mutein rhIFNα2b tended to show better proapoptotic activity reflected by flow cytometric data, protein expression of pSTAT1, and DNA expression of caspase 3.
Keywords: Interferon alpha 2b; Antiproliferation; Apoptosis; p21k1; p27; Caspase 3; pSTAT1; Flow cytometri; Mutein Interferon alpha 2b; Antiproliferation; Apoptosis; p21k1; p27; Caspase 3; pSTAT1; Flow cytometri; Mutein
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

RACHMAWATI, H.; JESSICA, A.; SUMIRTAPUTRA, Y.C.; RETNONINGRUM, D.S.; ADLIA, A.; NINGRUM, R.A. Removing a Cystein Group On Interferon Alpha 2b at Position 2 and 99 does Not Diminish Antitumor Activity of the Protein, Even Better. Sci. Pharm. 2016, 84, 113-130.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top